GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » Debt-to-Equity

Kadimastem (XTAE:KDST) Debt-to-Equity : -0.90 (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kadimastem Debt-to-Equity?

Kadimastem's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ₪7.37 Mil. Kadimastem's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ₪0.00 Mil. Kadimastem's Total Stockholders Equity for the quarter that ended in Jun. 2024 was ₪-8.14 Mil. Kadimastem's debt to equity for the quarter that ended in Jun. 2024 was -0.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kadimastem's Debt-to-Equity or its related term are showing as below:

XTAE:KDST' s Debt-to-Equity Range Over the Past 10 Years
Min: -13.49   Med: -0.28   Max: 36.49
Current: -0.9

During the past 11 years, the highest Debt-to-Equity Ratio of Kadimastem was 36.49. The lowest was -13.49. And the median was -0.28.

XTAE:KDST's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XTAE:KDST: -0.90

Kadimastem Debt-to-Equity Historical Data

The historical data trend for Kadimastem's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem Debt-to-Equity Chart

Kadimastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.77 -1.61 0.39 21.87 -1.45

Kadimastem Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.02 21.87 36.49 -1.45 -0.90

Competitive Comparison of Kadimastem's Debt-to-Equity

For the Biotechnology subindustry, Kadimastem's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kadimastem's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadimastem's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kadimastem's Debt-to-Equity falls into.



Kadimastem Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kadimastem's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Kadimastem's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kadimastem  (XTAE:KDST) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Kadimastem Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kadimastem's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Kadimastem Business Description

Traded in Other Exchanges
N/A
Address
Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR
Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem Headlines

No Headlines